Trial Information

Summary: Research study of an investigational medication for Severe Depression

A Phase 4, multicenter, randomized, open-label, active comparator, parallel group trial for the evaluation of duloxetine versus other antidepressants in the treatment of patients with severe baseline symptoms of major depressive disorder.

Length of study 15 weeks

Number of office visits: Up to 8

Qualified participants will receive study medication and study related services at no cost. Additionally, there is compensation for time and travel for qualified participants.

You may qualify for this study if you:

  • Are 18 years of age or older
  • Are without serious health problems
  • Are not addicted to drugs or alcohol
  • Do not have certain conditions such as Bipolar Disorder or Schizophrenia

Contact:

California Neuroscience Research Medical Group, Inc.
4835 Van Nuys Blvd., Suite #104
Sherman Oaks, CA 91403
Telephone: (818) 990-2671
Email:

Profile Page: California Neuroscience Research Medical Group, Inc., Sherman Oaks, CA

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:


Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 19, 2008 at 2:42:56 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA